Kumar S, Hammerschlag MR. Acute respiratory infection due to Chlamydia pneumoniae: current status of diagnostic methods. Clin Infect Dis. 2007;44:568-576.
Rockey DD, Lenart J, Stephens RS. Genome sequencing and our understanding of Chlamydiae. Infect Immun. 2000;68:5473-5479.
1. Kumar S, Hammerschlag MR. Acute respiratory infection due to Chlamydia pneumoniae: current status of diagnostic methods. Clin Infect Dis. 2007;44:568-576.
2. Hyman CL, Roblin PM, Gaydos CA, et al. The prevalence of asymptomatic nasopharyngeal carriage of Chlamydia pneumoniae in subjectively healthy adults: assessment by polymerase chain reaction-enzyme immunoassay and culture. Clin Infect Dis. 1995;20:1174-1178.
3. Rockey DD, Lenart J, Stephens RS. Genome sequencing and our understanding of Chlamydiae. Infect Immun. 2000;68:5473-5479.
4. Csango PA, Haraldstad S, Pedersen JE, et al. Respiratory tract infection due to Chlamydia pneumoniae in military personnel. Scand J Infect Dis Suppl. 1997;104:26-29.
5. Troy CJ, Peeling RW, Ellis AG, et al. Chlamydia pneumoniae as a new source of infectious outbreaks in nursing homes. JAMA. 1997;277:1214-1218.
6. Nakashima K, Tanaka T, Kramer MH, et al. Outbreak of Chlamydia pneumoniae infection in a Japanese nursing home, 1999-2000. Infect Control Hosp Epidemiol. 2006;27:1171-1177.
7. Kumar S, Kutlin S, Roblin P, et al. Isolation and antimicrobial susceptibilities of chlamydial isolates from Western barred bandicoots. J Clin Microbiol. 2007;45:392-394.
8. Hyman CL, Augenbraun MH, Roblin PM, et al. Asymptomatic respiratory tract infection with Chlamydia pneumoniae TWAR. J Clin Microbiol. 1991;29:2082-2083.
9. Falsey AR, Walsh EE. Transmission of Chlamydia pneumoniae. J Infect Dis. 1993;168:493-496.
10. Gray GC, Witucki PJ, Gould MT, et al. Randomized, placebo-controlled clinical trial of oral azithromycin prophylaxis against respiratory infections in a high-risk young adult population. Clin Infect Dis. 2001;33:983-989.
11. Kohlhoff SA, Hammerschlag MR. Treatment of chlamydial infections: 2014 update. Expert Opin Pharmacother. 2015;16:205-212.
12. Hammerschlag MR, Roblin PM. Microbiologic efficacy of levofloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae. Antimicrob Agents Chemother. 2000;44:1409.
13. Hammerschlag MR, Roblin PM. Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae. Int J Antimicrob Agents. 2000;15:149-152.
14. Block S, Hedrick J, Hammerschlag MR, et al. Mycoplasma pneumoniae and Chlamydia pneumoniae in community acquired pneumonia in children: comparative safety and efficacy of clarithromycin and erythromycin suspensions. Pediatr Infect Dis J. 1995; 14:471-477.
15. Harris J-A, Kolokathis A, Campbell M, et al. Safety and efficacy of azithromycin in the treatment of community acquired pneumonia in children. Pediatr Infect Dis J. 1998;17:865-871.
16. Roblin PM, Hammerschlag MR. Microbiologic efficacy of azithro-mycin and susceptibility to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community acquired pneumonia. Antimicrob Agents Chemother. 1998;42:194-196.
17. Hammerschlag MR, Chirgwin K, Roblin PM, et al. Persistent infection with Chlamydia pneumoniae following acute respiratory illness. Clin Infect Dis. 1992;14:178-182.
18. Emre U, Roblin PM, Gelling M, et al. The association of Chlamydia pneumoniae infection and reactive airway disease in children. Arch Pediatr Adolesc Med. 1994;148:727-732.
使用此内容应接受我们的免责声明。
BMJ临床实践的持续改进离不开您的帮助和反馈。如果您发现任何功能问题和内容错误,或您对BMJ临床实践有任何疑问或建议,请您扫描右侧二维码并根据页面指导填写您的反馈和联系信息*。一旦您的建议在我们核实后被采纳,您将会收到一份小礼品。
如果您有紧急问题需要我们帮助,请您联系我们。
邮箱:bmjchina.support@bmj.com
电话:+86 10 64100686-612
*您的联系信息仅会用于我们与您确认反馈信息和礼品事宜。
BMJ临床实践官方反馈平台